Bookmark and Share
BioAssay: AID 1478

qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent)

Cruzain (3.4.22.51) is a cysteine protease from the tropical parasite Trypanosoma cruzi. Dual qHTS experiment was performed against the NCGC compound collection in order to 1) identify novel inhibitors of the enzyme and 2) profile the compound collection for promiscuous inhibitors operating via colloidal aggregation (by performing detergent-free and detergent-containing comparison screens). more ..
_
   
 Tested Compounds
 Tested Compounds
All(195018)
 
 
Active(848)
 
 
Inactive(193140)
 
 
Inconclusive(1075)
 
 
 Tested Substances
 Tested Substances
All(197846)
 
 
Active(860)
 
 
Inactive(195907)
 
 
Inconclusive(1079)
 
 
AID: 1478
Data Source: NCGC (CRUZ374)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-01-02
Modify Date: 2010-02-19

Data Table ( Complete ):           Active    All
Target
BioActive Compounds: 848
Depositor Specified Assays
Show more
AIDNameTypeComment
1476qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent)confirmatoryqHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent)
2158Confirmation qHTS Assay for Inhibitors of CruzainconfirmatoryConfirmation qHTS Assay for Inhibitors of Cruzain
2249Probe Development Summary of Promiscuous Inhibitors (Artifacts) of CruzainsummaryProbe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain
2161qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain AssayconfirmatoryqHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay
2737Confirmation Competitive Binding Assay for Inhibitors of Cruzainconfirmatory
504656Inhibitors of Cruzain: Trypanosoma Cruzi Growth Inhibition Assayconfirmatory
2413Probe Summary: Docking False Negative Inhibitors of Cruzainsummary
493215Inhibitors of Cruzain: Benzimidazole Series - Round 1confirmatory
2383Probe Development Summary of Inhibitors of Cruzainsummary
Description:
Cruzain (3.4.22.51) is a cysteine protease from the tropical parasite Trypanosoma cruzi. Dual qHTS experiment was performed against the NCGC compound collection in order to 1) identify novel inhibitors of the enzyme and 2) profile the compound collection for promiscuous inhibitors operating via colloidal aggregation (by performing detergent-free and detergent-containing comparison screens). Cruzain was assayed by the use of fluorogenic coumarin-based substrate Z-FR-AMC: proteolytic cleavage releases AMC, whose fluorescence is measured at 360 nm excitation and 450 nm emission. Purified cruzain was supplied by the labs of Prof. James McKerrow and Brian Shoichet, UC San Francisco.

This assay had 0.01% Triton X-100 concentration. See also releated assay "qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent)" with 0.00005% Triton X-100.

See following references for additional details:

Jadhav A, et al. J Med Chem. 2010 Jan 14;53(1):37-51.
Mott BT, et al. J Med Chem. 2010 Jan 14;53(1):52-60.

Assay Provider: Shoichet, Brian; University of California, San Fancisco
Screening Center PI: Austin, C.P.
Screening Center: NIH Chemical Genomics Center [NCGC]
Protocol
Buffer: 100 mM Sodium Acetate, pH 5.5, 5 mM DTT, Triton X-100 concentration: 0.01%.

Reagents/Controls:
Buffer in columns 3 and 4 as negative control (no enzyme).
Substrate solution: 2 uM final concentration of Z-FR-AMC (catalog number I-1160, Bachem) dispensed throughout the plate.
Enzyme: 1.5 nM Cruzain final concentration in columns 1, 2, 5-48. Column 1 is neutral (100% activity). Column 2 contained titration of covalent inhibitor K11777, starting concentration 1 mM, then 1:2 dilution in duplicate).

Assay Steps:
Three uL of enzyme or buffer were dispensed to 1536-well Greiner black solid bottom plates. Compounds and controls (23 nL) were transferred via Kalypsys PinTool. The plates were incubated for 15 min at room temperature, and then 1 uL of substrate solution was added to start the reaction. The plates were immediately transferred to and read 4 times every 30 seconds for 2 min on ViewLux High-throughput CCD imager (Perkin-Elmer) using 360 nm excitation and 450 nm emission fluorescence protocol. The fluorescence intensity difference between the third and the first time points (time lapse of 60 seconds) was used to compute reaction progress.
Comment
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are likely fluorescent artifacts and are ranked lower than apparent inhibitors.

2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

3. For all active or inconclusive compounds that gave high background fluorescence (RFU > 40 for background read), PUBCHEM_ACTIVITY_SCORE is 1 and 'Phenotype' is set to "Fluorescent".

Keywords: NIH Roadmap, MLSCN, MLI, MLSMR, qHTS, NCGC, Cruzain, Cruzipain, Aggregation, Chagas disease
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1PhenotypeIndicates type of activity observed: inhibitor, activator, fluorescent, cytotoxic, inactive, or inconclusive.String
2Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
3EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
4Analysis CommentAnnotation/notes on a particular compound's data or its analysis.String
5Curve_DescriptionA description of dose-response curve quality. A complete curve has two observed asymptotes; a partial curve may not have attained its second asymptote at the highest concentration tested. High efficacy curves exhibit efficacy greater than 80% of control. Partial efficacies are statistically signficant, but below 80% of control.String
6Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
7Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
8Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
9Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
10Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
11Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
12Excluded_PointsWhich dose-response titration points were excluded from analysis based on outlier analysis. Each number represents whether a titration point was (1) or was not (0) excluded, for the titration series going from smallest to highest compound concentrations.String
13Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
14Compound QCSource of compound QCString

* Activity Concentration.
Additional Information
Grant Number: DA024891-01

Data Table (Concise)
PageFrom: